Nexalin Technology, Inc. NXL
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
4/9
Piotroski F — financial health
-68.21
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $301,647 | -$8.2M | $240,274 | — | $3.7M |
| 2024 | $168,721 | -$7.6M | $132,128 | — | $3.7M |
| 2023 | $110,748 | -$4.6M | $85,060 | — | $3.2M |
| 2022 | $1.3M | -$1.7M | $958,145 | — | $5.5M |
| 2021 | $144,065 | -$6.1M | $122,623 | — | -$1.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| OSSER LEONARD | 10% owner | 2025-09-29 | Grant | 83,333 | — |
| Owens David | Chief Medical Officer | 2025-09-29 | Grant | 36,459 | — |
| Hu Ben | director | 2025-09-29 | Grant | 36,459 | — |
| Kazden Alan | director | 2025-09-29 | Grant | 36,459 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -68.21 (distress)
- Working capital / assets 0.736
- Retained earnings / assets -20.035
- EBIT / assets -1.81
- Equity / liabilities 4.224
Source: SEC EDGAR filings · CIK 0001527352 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.